Quantcast

Here's Why Teva Pharma Stock Is Soaring Today


Shutterstock photo

Shares of Teva Pharmaceuticals TEVA gained more than 10% in early morning trading Thursday after news emerged Wednesday that Warren Buffett's Berkshire Hathaway BRK.B took a massive stake in the struggling drugmaker during the fourth quarter.

Berkshire disclosed the holding-worth about $358 million-in the famous conglomerate's latest quarterly filing. Shares of Teva were down nearly 50% over the past year before Buffett's firm announced its stake.

The purchase indicates that Teva's recent slump has dragged the stock into the value territory that Buffett typically targets. The generic drug giant has faced significant headwinds lately, but Berkshire could be well positioned to benefit from the company's planned turnaround.

Nevertheless, a quick glance at Teva's current fundamental situation suggests that this turnaround may be easier said than done. The firm's core business has been hammered by a lower U.S. generic drug prices and increased competition-causing management to take out massive loans to protect from its shrinking profit margins.

After losing half of its value in 2016, Teva initiated a strategic shift meant to address its new debt issues and identify its strongest businesses. Reports from last summer indicated that the company was looking to ramp up asset sales, putting several of its global brands-including its respiratory treatment assets and the Iceland-based drugmaker Medis-on the chopping block.

But Teva's commitment to solving its looming debt crisis was not enough for investors in 2017, and the stock shed another 50% over the course of a difficult year.

"We believe that Teva's disappointing generic business performance will take more time to improve given a combination of the generic industry's intensifying secular challenges and Teva's own difficulty in executing on its pipeline," wrote Morgan Stanley analyst David Risinger in August.

Teva is currently sporting a Zacks Rank #4 (Sell). But the stock does hold an "A" grade for Value in our Style Scores system, and these attractive valuation metrics likely inspired Buffett and Berkshire to make a play on the stock.

Want more analysis from this author? Make sure to follow @ Ryan_McQueeney on Twitter!

The Hottest Tech Mega-Trend of All

Last year, it generated $8 billion in global revenues. By 2020, it's predicted to blast through the roof to $47 billion. Famed investor Mark Cuban says it will produce "the world's first trillionaires," but that should still leave plenty of money for regular investors who make the right trades early.

See Zacks' 3 Best Stocks to Play This Trend >>


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

Berkshire Hathaway Inc. (BRK.B): Free Stock Analysis Report

Teva Pharmaceutical Industries Limited (TEVA): Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.



This article appears in: Investing , Stocks
Referenced Symbols: BRK.B , TEVA



More from Zacks.com

Subscribe






Zacks.com
Contributor:

Zacks.com

Equity Research










Research Brokers before you trade

Want to trade FX?